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Background
Aggregation of therapeutic antibody is generally
occurred in its manufacturing process, and should be
suppressed and removed because its potential risk for
unexpected immune response [1,2]. Protein A affinity
chromatography is the first purification step in the
monoclonal antibody manufacturing. Although the affi-
nity purification is a powerful technique, high affinity
between protein A and antibody requires acidic condi-
tion (below pH 3.0) to elute the captured antibody
molecules. Exposure to acidic condition can induce the
denaturation and aggregation of antibody molecules,
demonstrating the necessity of novel strategy to reduce
the antibody aggregation in the affinity purification pro-
cess. Here we introduced a novel affinity purification
strategy, thermo responsive protein A (TRPA) resin.
TRPA is an engineered protein A ligand which adopts
folded structure under 10°C and unfolds at moderate
temperature, above 25°C. TRPA resin can control cap-
ture and elution of antibody by changing column tem-
perature, making it possible to elute antibody molecules
without low pH condition. In this study, we applied the
TRPA column to the purification of Ex3 humanized IgG-
like single-chained bispecific diabody-Fc (Ex3-scDb-Fc)
[3]. The bispecific diabody is the promising candidate for
next-generation therapeutic antibody, whereas it shows
aggregation tendency. Furthermore, we observed the
time-dependent formation of antibody aggregation in the
culture process of the recombinant Chinese hamster
ovary (CHO) cell line with TRPA column.
Materials and methods
CHO Top-H cell line producing the Ex3-scDb-Fc [4] was
cultivated in a 1L-glass bioreactor with working volume of
750mL serum-free medium. Viable cell densities and anti-
body concentrations in the medium was determined with
Vi-Cell XR™ cell viability analyzer (Beckman Coulter) and
by ELISA, respectively. The bispecific diabody was purified
with conventional protein A (PA) column or thermo
responsive protein A (TRPA) column, which were con-
nected with AKTA prime plus (GE Healthcare). Elution of
antibody was performed by acidic pH solution (pH2.7) for
PA column and by raising column temperature to 45°C
for TRPA column. Aggregate formation was analyzed with
Superdex 200 10/30 GL column (GE Healthcare).
Results and discussion
Performance of TRPA column in the affinity purification
of bispecific diabody-Fc
We purified the Ex3-scDb-Fc from the culture superna-
tant of CHO Top-H cell line with PA and TRPA column.
Compared to the conventional protein A column (PA),
purification with TRPA column showed no precipitation
of the aggregated scDb-Fc after the elution. Figure 1A is
the size exclusion chromatography (SEC) profiles, show-
ing that TRPA purification substantially reduced the for-
mation of soluble large aggregates as compared to the PA
purification including the exposure to acidic pH condi-
tion. Collectively, the above results demonstrate that
TRPA column is highly effective in preventing the forma-
tion of precipitated and soluble aggregates in the affinity
purification of the bispecific diabody-Fc.
Dynamical aggregation analysis in the cell culture process
SEC profile of TRPA-purified Ex3-scDb-Fc would cor-
rectly reflect the status of antibody aggregation in CHO
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cell culture, because no further aggregation was induced
in the affinity purification process with TRPA column as
compared with that with conventional PA. Although
secreted antibody is known to aggregate during cell cul-
ture process [1,2], the underlying mechanism is still
poorly understood due to the lack of observation of the
aggregation process. We applied the TRPA column to
dynamical aggregation analysis of Ex3-scDb-Fc in CHO
cell culture. Culture supernatants from exponential to
stationary growth phase in a bioreactor operation were
sampled, and the bispecific diabody was purified with
TRPA column and analyzed by Size exclusion chroma-
tography. The procedure makes it possible to observe
the time-dependent formation of antibody aggregates in
CHO cell culture. In Figure 1B, the peak areas of large
aggregates were plotted as a function of cultivation time,
showing that after 250 hours the amounts of aggregated
Ex3-scDb-Fc were abruptly increased in time dependent
manner. The results suggest a nucleation-dependent
aggregation model for antibody aggregation, where the
accumulation of aggregation nucleus is the rate limiting
step and then the nucleus induces the formation of
large aggregates in CHO cell culture. The bispecific dia-
body in this study has a tendency to aggregate during
the CHO cell culture process, demonstrating the neces-
sity of the novel cell culture strategy to suppress the
aggregates formation.
Conclusions
We propose the Thermo Responsive Protein A (TRPA)
column as a novel strategy to reduce the antibody
aggregation in an affinity purification process and to
analysis the aggregation during the cell culture process.
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Figure 1 (A) Size-exclusion chromatography showing the elution profiles of Ex3-scDb-Fc purified with TRPA (red) and PA (blue). (B)
Time-dependent formation of aggregates in CHO cell culture.
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